Navigation Links
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Date:2/9/2011

tion of Diabetic Retinopathy (DR), a disease affecting the blood vessels of the retina.  Clinically significant DME is a leading cause of blindness in younger adults (under 50).  Clinically significant DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision.  Fluid in the macula can cause severe vision loss or blindness.

Approximately 370,000 Americans currently suffer from clinically significant DME, with 95,000 new cases arising each year.  According to the American Diabetes Association, more than 18 million Americans currently suffer from diabetes, and many other people are at risk for developing diabetes.  With the incidence of diabetes steadily climbing, it is projected that up to 10 percent of all patients with diabetes will develop DME during their lifetime.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statement
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regeneron Announces Presentation at the ISI Annual Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
3. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
4. Christine A. Poon Elected to Regeneron Board of Directors
5. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
6. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
7. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Regeneron Increases Size of Public Offering of Common Stock
9. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
10. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/rt3mhz/deciphering ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing Demands ... It has been publicly recognized that global ... series of challenges in the recent years. The ... in small molecule product manufacturing; increasingly challenging process ...
(Date:7/7/2015)... 7, 2015   Decision Resources Group ... dialysis patient management in the U.S. versus the ... U.S. and EU5 nephrologists from approximately 1,870 dialysis ... the most commonly used renal medications in dialysis ... considerably between the two regions.      Other ...
(Date:7/7/2015)... BANGALORE , July 7, 2015 ... innovative clinical trial data management solutions, has been featured ... publication named " EDC and eCOA / ePRO Market ... is one of the leading providers of research and ... 22 EDC and eCOA / ePRO tools in the ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Minimally Invasive Surgery Symposium (MISS) will include discussion of ... surgery, single-port bariatric surgery, transoral gastroplasty, and other "frontier" ... by MISS Executive Director Philip R Schauer, MD, on ... , The five-day CME conference, which will be held ...
... Oct. 27 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and ... McDermott, Endologix President and Chief Executive Officer, said, "Our ... sales of new products by our domestic sales force ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 3Endologix Reports 47% Third Quarter 2009 Revenue Growth 4Endologix Reports 47% Third Quarter 2009 Revenue Growth 5Endologix Reports 47% Third Quarter 2009 Revenue Growth 6Endologix Reports 47% Third Quarter 2009 Revenue Growth 7Endologix Reports 47% Third Quarter 2009 Revenue Growth 8
(Date:7/7/2015)... ... July 07, 2015 , ... Celestix Networks, the leading ... CelestixFederated VA Series virtual appliances. These virtual platforms expand the existing physical ... have proven to simplify the on-premises deployment of unified remote access and single ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today announced ... access its antibody combination therapy (ACT) technology platform. The platform has the ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Detroit was the site of the National Baptist Convention 110th Annual Session of ... encouraging and promoting the collaboration of churches and their congregations, medical professionals and ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri , ... treatments. A professional teeth whitening is one of the fastest, easiest ways to brighten ... they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, patients ...
Breaking Medicine News(10 mins):Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3
... after surgery eases concern over side effects, study finds ... counseling appears to benefit men who have all or ... early-stage prostate cancer, says a U.S. study. , ... receive one of the following: two 60- to 90-minute ...
... Corporation of America (Nasdaq: DCAI ) announced ... with the University of Cincinnati , College of ... the next three years, will be used solely to ... kidney disease. This multi-year agreement gives Dialysis Corporation of ...
... teach my body to stop craving food? How can I ... of anesthesia? Can long-term use of Fosamax actually increase risk ... medical experts and authors answer all your questions at the ... by Fox 5 medical reporter Dr. Sapna Parikh. The event ...
... legislators brainstorm ways to reduce significant levels of ... continues to find innovative solutions to educate the ... abuse. Innocorp President Michael Aguilar announced today that ... Mr. Glynn Birch, has been named as Innocorp,s ...
... being phased out, experts note, , , WEDNESDAY, April 8 ... are found in a wide range of products, and ... not boost risks for a range of malignancies ... chemicals, perfluorooctanoate and perfluorooctanesulfonate (PFOA, PFOS) have for decades ...
... New Yorkers have elevated levels of cotinine in their ... toxic second-hand smoke in concentrations high enough to leave ... breakdown, is not harmful itself but signals exposure to ... this week in the journal Nicotine and Tobacco ...
Cached Medicine News:Health News:Stress Management Battles Prostate Cancer Anxiety 2Health News:Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine 2Health News:Best-selling authors and physicians from NYP/Weill Cornell discuss diet, surgery and bone health 2Health News:Former MADD National President Joins Innocorp, ltd. 2Health News:Common Industrial Chemicals May Not Boost Cancer Risk 2Health News:Common Industrial Chemicals May Not Boost Cancer Risk 3Health News:Blood tests reveal tobacco smoke residues in non-smoking New Yorkers 2Health News:Blood tests reveal tobacco smoke residues in non-smoking New Yorkers 3Health News:Blood tests reveal tobacco smoke residues in non-smoking New Yorkers 4
... The Stabilizing Ankle support features ... which lock the calcaneus into ... eversion and inversion. The full-circumference ... and stability. Ideal for chronic ...
... Wee Walker Pediatric Boot is ... pediatric boot that offers superior ... Only two sizes are offered ... sizes will fit left or ...
... Boot is designed as a flexible ... the mid-tibia or fibula to mid-foot ... support. The Bledsoe EZ Set PTB ... motion from 20 degrees of dorsi-flexion ...
... as a flexible and attractive alternative to casting ... and also for second and third degree ankle ... Bledsoe Hi-Top Boot but offers similar support. The ... range of motion from 20 degrees of dorsi-flexion ...
Medicine Products: